Precision medicine for pediatric cardiomyopathy: lessons from pediatric oncology

From the report

Nature Cardiovascular Research, Published online: 23 October 2026; doi:10.1038/s44161-026-00900-9The greatest barrier to precision medicine in pediatric cardiomyopathy may no longer be biology but classification. Reclassifying cardiomyopathy into mechanism-specific rare diseases could provide an operational framework for targeted therapies and precision trials.